Nyxoah SA
NYXH
Company Profile
Business description
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Contact
Rue Edouard Belin 12
Mont-Saint Guibert1435
BELT: +32 10222355
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
184
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.30 | 44.90 | 0.50% |
| CAC 40 | 8,151.38 | 0.74 | 0.01% |
| DAX 40 | 24,288.40 | 88.90 | 0.37% |
| Dow JONES (US) | 48,134.89 | 183.04 | 0.38% |
| FTSE 100 | 9,897.42 | 59.65 | 0.61% |
| HKSE | 25,747.34 | 56.81 | 0.22% |
| NASDAQ | 23,307.62 | 301.26 | 1.31% |
| Nikkei 225 | 50,480.76 | 973.55 | 1.97% |
| NZX 50 Index | 13,468.62 | 135.22 | 1.01% |
| S&P 500 | 6,834.50 | 59.74 | 0.88% |
| S&P/ASX 200 | 8,704.00 | 43.80 | 0.51% |
| SSE Composite Index | 3,915.18 | 24.74 | 0.64% |